IM19 CAR-T cells

PreclinicalCell therapy

BBeijing Immunochina Medical Science & Technology Co., Ltd.

IM19 CAR-T cells is one of 164 biologic programs targeting Systemic Lupus Erythematosus. It is currently in Preclinical.

Indications

Total Trials

Active Trials

163

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

LymphomaActive, not recruiting

Mantle Cell LymphomaActive, not recruiting

B-Cell Acute Lymphoblastic LeukemiaActive, not recruiting

Systemic Lupus ErythematosusPreclinical

Active, not recruiting

LymphomaPhase 1/Phase 2

Active, not recruiting

Mantle Cell LymphomaPhase 1/Phase 2

Active, not recruiting

B-Cell Acute Lymphoblastic LeukemiaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Oncaspar

SServier

Preclinical

15 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Zofran

Novartis

Preclinical

2 4

Tafasitamab

Incyte

Preclinical

7 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

Decadron

QQuince Therapeutics S.p.A.

PEG-Intron

1 8

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—9

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

3 10

Stem Cells

KKang Stem Biotech Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ARecruiting

Systemic Lupus Erythematosus

NCT06513429

Q2 2035

Phase 1/2Recruiting

Lymphoma

NCT04440436

Clinical

Trials by Indication[1]

B-cell acute lymphoblastic leukemia2 trials

Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia

Unknown status·BBeijing Immunochina Medical Science & Technology Co., Ltd.·Phase 1/2·NCT05309213·58 enrolled

Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia

Unknown status·BBeijing Immunochina Medical Science & Technology Co., Ltd.·Phase 1·NCT05480501·9 enrolled

Systemic Lupus Erythematosus1 trial

IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE)

Recruiting·PPeking University Third Hospital·N/A·NCT06513429·6 enrolled

Lymphoma1 trial

Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients

Recruiting·BBeijing Immunochina Medical Science & Technology Co., Ltd.·Phase 1/2·NCT04440436·52 enrolled

Mantle Cell Lymphoma1 trial

Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Unknown status·BBeijing Immunochina Medical Science & Technology Co., Ltd.·Phase 1/2·NCT05155215·68 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for IM19 CAR-T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IM19 CAR-T cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IM19 CAR-T cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Immunochina Medical Science & Technology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Preclinical[1]
Company: BBeijing Immunochina Medical Science & Technology Co., Ltd.

IM19 CAR-T cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2035

Trials by Indication[1]

B-cell acute lymphoblastic leukemia2 trials

Systemic Lupus Erythematosus1 trial

Lymphoma1 trial

Mantle Cell Lymphoma1 trial

References

Drug Info

Quick Facts

Related News